PIK3CG and cancer: FOXO is frequently inactive in dividing cells associated with an active PI3K pathway, for example in benign or malignant tumors or in clonally expanding lymphocytes, and becomes active when cells are treated with drugs that inhibit the PI3K pathway [64,67].